Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9869119 | 0.98 | SIGMAR1 (0.59) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL5541146 | 0.84 | SIGMAR1 (0.60) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL14601668 | 0.84 | SIGMAR1 (0.60) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL9726233 | 0.84 | SIGMAR1 (0.61) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL9867159 | 0.84 | SIGMAR1 (0.60) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL6162058 | 0.84 | SIGMAR1 (0.60) | SIGMAR1HTR1AKCNA3 | |
| Hydrochloric Acid SCHEMBL9868303 | 0.83 | SIGMAR1 (0.59) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL256663 | 0.83 | SIGMAR1 (0.63) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL7297566 | 0.83 | SIGMAR1 (0.63) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL5544346 | 0.83 | SIGMAR1 (0.63) | SIGMAR1HTR1AKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| WO-2009051815-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008030887-A2 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-5130313-A | Central nervous system disorders, cardiovascular disorders or gastrointestinal disorders | RHONE-POULENC SANTE (FR) | 1992-07-14 | — | — | US | disclosed |
| US-4999355-A | Antiserotonine agents | RHONE-POULENC (FR) | 1991-03-12 | — | — | US | disclosed |
| US-4617309-A | Sulfur-containing indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | disclosed |
| EP-0105397-B1 | SULPHURIC INDOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 1986-07-16 | — | — | EP | disclosed |
| EP-0105397-A1 | Sulphuric indole derivatives | MERCK PATENT GmbH (DE) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | PARP1, PARP2, PARP3 | SIGMAR1 4587/4885HTR1A 2229/4885KCNA3 4214/4885 |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | PARP3, PARP1, PARP15 | SIGMAR1 4571/4885HTR1A 1869/4885KCNA3 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.